Topical corticosteroids

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

9 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

1

Amlitelimab

Sanofi

Phase 3

32

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

23

Topical corticosteroids

Sanofi

Phase 3

24

JNJ-95475939

Johnson & Johnson

Phase 2

15

JNJ-95597528

Johnson & Johnson

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Dermatitis, Atopic2 trials

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Enrolling by invitation·Sanofi·Preclinical·NCT05492578·1,663 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

Recruiting·Sanofi·Phase 3·NCT06241118·636 enrolled

Details

Drug Info

Related News